Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.

This study provides preclinical proof-of-concept that combined treatment of EZH2 inhibitor with AR antagonist results in synergistic anticancer effects opening new possibilities for treatment of CRPC tumors.
PMID: 32805266 [PubMed - as supplied by publisher]

Source: Toxicology and Applied Pharmacology - August 13, 2020 Category: Toxicology Authors: Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, Gupta S Tags: Toxicol Appl Pharmacol Source Type: research